Post-Hoc: AI bio needs to heed the overhyped history of CRISPRnews2025-05-22T11:00:10+00:00May 22nd, 2025|Endpoints News|
Pathos AI collects $365M to fuel data-driven oncology studiesnews2025-05-15T14:44:09+00:00May 15th, 2025|Endpoints News|
Exclusive: Datavant will acquire Aetion, double life sciences teamnews2025-05-15T12:30:38+00:00May 15th, 2025|Endpoints News|
AI biotech Insilico Medicine goes for third attempt at Hong Kong IPOnews2025-05-09T09:15:26+00:00May 9th, 2025|Endpoints News|
AI-focused biotech insitro cuts 22% of staff, citing ‘tumultuous market’news2025-05-08T18:22:26+00:00May 8th, 2025|Endpoints News|
AI biotech Recursion cuts pipeline to ‘sharpen focus’news2025-05-05T15:17:46+00:00May 5th, 2025|Endpoints News|
AI biotech Iambic debuts next-gen model Enchant for drug R&Dnews2025-05-05T12:30:05+00:00May 5th, 2025|Endpoints News|
Pathos AI gets AstraZeneca funding as biotech plans to raise up to $400Mnews2025-05-02T14:55:42+00:00May 2nd, 2025|Endpoints News|
Future House debuts free AI agent for science platformnews2025-05-01T15:30:48+00:00May 1st, 2025|Endpoints News|
Exclusive: AI biotech Stately Bio raises $12M for cell imagingnews2025-05-01T11:00:08+00:00May 1st, 2025|Endpoints News|
